1-20 of 43
Daniel D. Von Hoff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Vitamin A Metabolism and Resistance of Hepatic Metastases to Immunotherapy

Open Access
Peter C. Jones, Daniel D. Von Hoff
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2025) 24 (3): 345–353.
https://doi.org/10.1158/1535-7163.MCT-24-0367
Published: 04 March 2025
View articletitled, Vitamin A Metabolism and Resistance of Hepatic Metastases to Immunotherapy
Open the PDF for Vitamin A Metabolism and Resistance of Hepatic Metastases to Immunotherapy in another window
Journal Articles

Abstract LBA024: IL-36γ induces immune infiltration and suppresses tumor growth in a syngeneic mouse model for pancreatic cancer

Free
Kuntal Halder, Daniel D Von Hoff, Haiyong Han
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): LBA024.
https://doi.org/10.1158/1535-7163.TARG-21-LBA024
Published: 01 December 2021
View articletitled, Abstract LBA024: IL-36γ induces immune infiltration and suppresses tumor growth in a syngeneic mouse model for pancreatic cancer
Journal Articles

Abstract A142: Drug combination screen to identify novel synergy with Minnelide

Free
Nanyun Tang, Chris Sereduk, Ashok Saluja, Mohana Velagapudi, Haiyong Han, Daniel D Von Hoff, Hongwei Holly Yin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A142.
https://doi.org/10.1158/1535-7163.TARG-19-A142
Published: 01 December 2019
View articletitled, Abstract A142: Drug combination screen to identify novel synergy with Minnelide
Journal Articles

Abstract C053: NP-G2-044, a novel fascin inhibitor, blocks tumor metastasis and increases antitumor immune response

Free
Vincent Chung, Frank Tsai, Komal Jhaveri, Yufeng Wang, Daniel D Von Hoff, Edward G Garmey, J. Jillian Zhang, Xin-Yun Huang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C053.
https://doi.org/10.1158/1535-7163.TARG-19-C053
Published: 01 December 2019
View articletitled, Abstract C053: NP-G2-044, a novel fascin inhibitor, blocks tumor metastasis and increases antitumor immune response
Journal Articles

Abstract A099: Acoustic Cluster Therapy enhances the efficacy of chemotherapeutic regimens in patient-derived xenograft mouse models for pancreatic ductal adenocarcinoma

Free
Serina Ng, Andrew Healey, Svein Kvåle, Spiros Kotopoulis, Daniel D Von Hoff, Per Christian Sontum, Haiyong Han
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A099.
https://doi.org/10.1158/1535-7163.TARG-19-A099
Published: 01 December 2019
View articletitled, Abstract A099: Acoustic Cluster Therapy enhances the efficacy of chemotherapeutic regimens in patient-derived xenograft mouse models for pancreatic ductal adenocarcinoma
Journal Articles

CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma

Free
Gargi Maity, Arnab Ghosh, Vijayalaxmi Gupta, Inamul Haque, Sandipto Sarkar, Amlan Das, Kakali Dhar, Sneha Bhavanasi, Sumedha S. Gunewardena, Daniel D. Von Hoff, Sanku Mallik, Suman Kambhampati, Sushanta K. Banerjee, Snigdha Banerjee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (4): 788–800.
https://doi.org/10.1158/1535-7163.MCT-18-0899
Published: 01 April 2019
View articletitled, CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma
Open the PDF for CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract LB-B27: Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts

Free
Emily Rodela, Pawan Noel, Shaimaa Hussein, Yin C. Lin, Daniel D. Von Hoff, Haiyong Han
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B27.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B27
Published: 01 January 2018
View articletitled, Abstract LB-B27: Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts
Journal Articles

Abstract C106: CBP501 potentiates the appearance of cisplatin-induced indicators of immunogenic cell death and promotes anti-tumor effects in an immuno-competent mouse model

Free
Keiichi Sakakibara, Takuji Sato, Donald W. Kufe, Daniel D. Von Hoff, Takumi Kawabe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C106.
https://doi.org/10.1158/1535-7163.TARG-15-C106
Published: 01 December 2015
View articletitled, Abstract C106: CBP501 potentiates the appearance of cisplatin-induced indicators of immunogenic cell death and promotes anti-tumor effects in an immuno-competent mouse model
Journal Articles

Abstract A110: CBP501 suppresses cell migration, invasion and epithelial-mesenchymal transition (EMT) in non-small cell lung carcinoma

Free
Naoya Saito, Naoki Mine, Donald W. Kufe, Daniel D. Von Hoff, Takumi Kawabe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A110.
https://doi.org/10.1158/1535-7163.TARG-15-A110
Published: 01 December 2015
View articletitled, Abstract A110: CBP501 suppresses cell migration, invasion and epithelial-mesenchymal transition (EMT) in non-small cell lung carcinoma
Journal Articles

Abstract A112: Observed separation of survival curves by WBC in CBP501-treated patients leads to experimental identification of macrophage functions suppressed by CBP501

Free
NAOKI MINE, Sayaka Yamamoto, Naoya Saito, Takuji Sato, Keiichi Sakakibara, Donald W. Kufe, Daniel D. Von Hoff, Takumi Kawabe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A112.
https://doi.org/10.1158/1535-7163.TARG-15-A112
Published: 01 December 2015
View articletitled, Abstract A112: Observed separation of survival curves by WBC in CBP501-treated patients leads to experimental identification of macrophage functions suppressed by CBP501
Journal Articles

Abstract C138: Targeting macropinocytosis in pancreatic cancer

Free
James Hunt, Serina Ng, Clifford Whatcott, Daniel D. Von Hoff, Haiyong Han
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C138.
https://doi.org/10.1158/1535-7163.TARG-15-C138
Published: 01 December 2015
View articletitled, Abstract C138: Targeting macropinocytosis in pancreatic cancer
Journal Articles

Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study

Free
Jason M. Summa, Daniel D. Von Hoff, Jasgit C. Sachdev, Monica M. Mita, Patricia M. LoRusso, Peter D. Eisenberg, Howard A. Burris, Lowell L. Hart, Hagop Youssoufian, Donald M. Parsons, Susan C. Low
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B144.
https://doi.org/10.1158/1535-7163.TARG-15-B144
Published: 01 December 2015
View articletitled, Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study
Journal Articles

Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro

Free
Naoki Mine, Sayaka Yamamoto, Donald W. Kufe, Daniel D. Von Hoff, Takumi Kawabe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (9): 2215–2225.
https://doi.org/10.1158/1535-7163.MCT-13-0808
Published: 02 September 2014
View articletitled, Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
Open the PDF for Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro in another window
Includes: Supplementary data
Journal Articles

Abstract A120: A Phase Ib study of CC-486 (Oral Azacitidine) as a priming agent for carboplatin or NAB-paclitaxel in subjects with relapsed and refractory solid tumors.

Free
Patricia LoRusso, Drew Rasco, Johanna Bendell, Jasgit Sachdev, Ramesh Ramanathan, Glenn Weiss, Pamela Munster, William J. Edenfield, Kejian Liu, Anne Blackwood-Chirchir, Jorge DiMartino, Jorge DiMartino, Daniel D. Von Hoff
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A120.
https://doi.org/10.1158/1535-7163.TARG-13-A120
Published: 01 November 2013
View articletitled, Abstract A120: A Phase Ib study of CC-486 (Oral Azacitidine) as a priming agent for carboplatin or NAB-paclitaxel in subjects with relapsed and refractory solid tumors.
Journal Articles

Abstract B217: A Phase I study of CC-486 (oral azacitidine) to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of azacitidine administered alone and in combination with carboplatin or ABI-007 (NAB-paclitaxel) in subjects with solid tumors.

Free
Eric Laille, Aaron N. Nguyen, Gengxi Chen, Drew Rasco, Patricia LoRusso, Daniel D. Von Hoff, Johanna Bendell, Pamela Munster, William J. Edenfield, Ramesh Ramanathan, Michael B. Gonzalez, Anne Blackwood-Chirchir, Jorge DiMartino
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B217.
https://doi.org/10.1158/1535-7163.TARG-13-B217
Published: 01 November 2013
View articletitled, Abstract B217: A Phase I study of CC-486 (oral azacitidine) to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of azacitidine administered alone and in combination with carboplatin or ABI-007 (NAB-paclitaxel) in subjects with solid tumors.
Journal Articles

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

Free
Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, Mayuko Omori, Nanni Huser, Nicole Streiner, Caroline B. Ho, Kenna Anderes, Chris Proffitt, Sean E. O'Brien, John K. C. Lim, Daniel D. Von Hoff, David M. Ryckman, William G. Rice, Denis Drygin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 994–1005.
https://doi.org/10.1158/1535-7163.MCT-11-0613
Published: 08 April 2012
View articletitled, CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
Open the PDF for CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract B152: Modulating the activity of nerve growth factor (NGF) and its receptors tropomyosin-related kinase A (TRKA) and p75 neurotrophin receptor (p75NTR) in perineural invasion (PNI) in pancreatic cancer.

Free
Aditi A. Bapat, Ruben M. Munoz, Saaiqa Maredia, Daniel D. Von Hoff, Haiyong Han
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B152.
https://doi.org/10.1158/1535-7163.TARG-11-B152
Published: 12 November 2011
View articletitled, Abstract B152: Modulating the activity of nerve growth factor (NGF) and its receptors tropomyosin-related kinase A (TRKA) and p75 neurotrophin receptor (p75NTR) in perineural invasion (PNI) in pancreatic cancer.
Journal Articles

Abstract B213: Isolation of muscle fatigue substance(s) with antitumor activities.

Free
Ruben M. Munoz, Haiyong Han, Daniel D. Von Hoff, Stanley Hoffman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B213.
https://doi.org/10.1158/1535-7163.TARG-11-B213
Published: 12 November 2011
View articletitled, Abstract B213: Isolation of muscle fatigue substance(s) with antitumor activities.
Journal Articles

CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin

Free
Naoki Mine, Sayaka Yamamoto, Naoya Saito, Satoshi Yamazaki, Chikako Suda, Machiyo Ishigaki, Donald W. Kufe, Daniel D. Von Hoff, Takumi Kawabe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (10): 1929–1938.
https://doi.org/10.1158/1535-7163.MCT-10-1139
Published: 09 October 2011
View articletitled, CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin
Open the PDF for CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin in another window
Includes: Supplementary data
Journal Articles

Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer

Free
David L. Schwartz, James A. Bankson, Robert Lemos, Jr., Stephen Y. Lai, Arun K. Thittai, Yi He, Galen Hostetter, Michael J. Demeure, Daniel D. Von Hoff, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 2057–2067.
https://doi.org/10.1158/1535-7163.MCT-09-0768
Published: 07 July 2010
View articletitled, Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer
Open the PDF for Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer in another window